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Netherton syndrome (NS; OMIM 256500) is 
an autosomal recessive disease regarded as one 
of the most severe heritable skin disorders af­
fecting newborns. NS involves both cutaneous 
and immunological abnormalities, including 
congenital ichthyosiform erythroderma, pro­
nounced peeling of the skin with detachment 
of the stratum corneum (SC) from the under­
lying epidermis, severe atopy with elevated 
serum IgE, and a characteristic hair shaft defect 
(Comel, 1949; Netherton, 1958; Judge et al., 1994; 
Hausser and Anton­Lamprecht, 1996). Collec­
tively, these detriments represent a serious chal­
lenge to neonate health and promote frequent 
complications, including hypernatremic dehy­
dration, failure to thrive and recurrent bacterial 
infections that can be life threatening. Previ­
ously, we established that the defective gene in 
NS is SPINK5 (Chavanas et al., 2000), which 
encodes the multidomain protease inhibitor, 
lymphoepithelial Kazal­type inhibitor (LEKTI). 
To date, the majority of SPINK5 mutations 
known to cause NS introduce a premature stop 
codon and result in a lack of detectable LEKTI 
expression (Hovnanian, 2013).
NS has brought into sharp focus the need 
to preserve the balance between proteolysis and 
inhibition in the epidermis. Similarly, LEKTI has 
emerged as a key regulator of epidermal prote­
olysis. Synthesized as a large (145­kD) polypro­
tein containing 15 Kazal domains, LEKTI is 
cleaved by furin to liberate a series of smaller 
fragments comprising one or more inhibitory 
units that target distinct protease subsets (Bitoun 
et al., 2003; Fortugno et al., 2011). LEKTI 
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Netherton syndrome (NS) is a severe genetic skin disease in which absence of a key 
protease inhibitor causes congenital exfoliative erythroderma, eczematous-like lesions, 
and atopic manifestations. Several proteases are overactive in NS, including kallikrein-
related peptidase (KLK) 5, KLK7, and elastase-2 (ELA2), which are suggested to be part 
of a proteolytic cascade initiated by KLK5. To address the role of KLK5 in NS, we have 
generated a new transgenic murine model expressing human KLK5 in the granular layer 
of the epidermis (Tg-KLK5). Transgene expression resulted in increased proteolytic activity 
attributable to KLK5 and its downstream targets KLK7, KLK14, and ELA2. Tg-KLK5 mice 
developed an exfoliative erythroderma with scaling, growth delay, and hair abnormalities. 
The skin barrier was defective and the stratum corneum was detached through desmo-
somal cleavage. Importantly, Tg-KLK5 mice displayed cutaneous and systemic hallmarks 
of severe inflammation and allergy with pruritus. The skin showed enhanced expression of 
inflammatory cytokines and chemokines, infiltration of immune cells, and markers of 
Th2/Th17/Th22 T cell responses. Moreover, serum IgE and Tslp levels were elevated. Our 
study identifies KLK5 as an important contributor to the NS proteolytic cascade and 
provides a new and viable model for the evaluation of future targeted therapies for NS or 
related diseases such as atopic dermatitis.
© 2014 Furio et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–
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of rapid dehydration (Yang et al., 2004; Descargues et al., 2005; 
Hewett et al., 2005).
In this study, we developed a new transgenic murine model 
expressing human KLK5 in the GR of the epidermis to assess 
the role of this protease in NS. KLK5 has been reported to 
cleave several desmosomal cadherins in vitro (Caubet et al., 
2004; Descargues et al., 2006), to activate PAR2 in cultured 
keratinocytes (Stefansson et al., 2008) and has a prominent 
role in the proposed KLK proteolytic activation cascade 
(Brattsand et al., 2005). This study reveals that elevated KLK5 
expression, even in the presence of functional Lekti, is suffi­
cient to trigger the majority of the clinical hallmarks of NS. 
These findings establish the important role of KLK5 in NS 
pathophysiology and demonstrate its considerable potential as 
a therapeutic target in this severe genetic skin disorder.
RESULTS
KLK5 is overexpressed in the GR of Tg-KLK5 mice
KLK5 is one of several proteases known to be overactive in 
NS, but its precise role in the disease remains to be defined 
(Descargues et al., 2005, 2006). To investigate the consequences 
of elevated KLK5 activity in vivo, we developed a transgenic 
murine model overexpressing human KLK5 under the control 
of the human involucrin promoter to target transgene expres­
sion in the GR of murine epidermis. The cDNA encoding 
human KLK5 full length sequence was fused to the FLAG tag 
and cloned downstream of the human involucrin promoter 
(Fig. 1 A). Animals carrying the transgene were identified 
using a PCR­based genotyping strategy as shown in Fig. 1 B. 
Western blot analysis using an anti­human KLK5 antibody 
confirmed expression of the exogenous protein in epidermal 
extracts of Tg­KLK5 animals (Fig. 1 C). We identified this 
protein as being KLK5­Flag by Western blot analysis with an 
anti­Flag antibody (Fig. 1 E). To confirm correct targeting 
of KLK5 to the GR, immunostaining of skin sections using 
the anti–human KLK5 antibody was performed. Murine 
Klk5 was detected at the GR–SC interface in WT epidermis, 
indicating cross reactivity of the human antibody with murine 
Klk5. In Tg­KLK5 epidermis, KLK5 staining was increased in 
the GR and SC, and faint in suprabasal cells (Fig. 1 D). Detec­
tion of the FLAG epitope in Tg­KLK5 epidermis showed 
predominant expression of exogenous KLK5 in the GR and 
SC, and confirmed restricted expression of the transgene to 
the upper epidermis (Fig. 1 F).
Tg-KLK5 mice develop a skin barrier defect associated with 
growth delay, hair abnormalities, and constant scratching
NS patients classically present at birth with scaling and general­
ized erythroderma (Hausser and Anton­Lamprecht, 1996). At 
birth, Tg­KLK5 animals were slightly smaller than WT litter­
mates and showed mild erythroderma (Fig. 2 A). Tg­KLK5 
mice also showed significantly lower body mass than WT lit­
termates (Fig. 2 A). To investigate epidermal barrier function in 
Tg­KLK5 mice, we first examined the ability of the skin to 
prevent penetration of an external dye solution in a whole­
mount assay. Tg­KLK5 neonates exhibited more patches of 
inhibits several members of the kallikrein­related peptidase 
(KLK) serine protease family (KLK5, KLK7, and KLK14; 
Deraison et al., 2007; Fortugno et al., 2011). Additionally, 
LEKTI has been recently suggested to inhibit caspase­14 
(Bennett et al., 2010). Collectively, these proteases are known 
to hold prominent roles in the SC. KLK5, KLK7, and KLK14 
contribute to desquamation by degrading desmosomal cad­
herins such as desmoglein­1 and desmocollin­1 (Caubet et al., 
2004; Fortugno et al., 2011) whereas caspase­14 is needed to 
complete the processing of filaggrin (Flg; Denecker et al., 
2007; Hoste et al., 2011). KLK5 and KLK14 are also able to 
stimulate proinflammatory and proallergic signals via protease­
activated receptor 2 (PAR2; Stefansson et al., 2008; Briot et al., 
2009) and KLK5 and KLK7 are linked to the maturation of 
cathelicidin antimicrobial peptides (Yamasaki et al., 2006). 
Thus, LEKTI coordinates the timing of several important 
proteolytic events in epidermal physiology and its absence in 
NS causes dysregulation of multiple pathways.
The development of Spink5­deficient mice provided the 
first opportunity to unravel the complex pathophysiology 
of NS in an in vivo experimental model (Yang et al., 2004; 
Descargues et al., 2005; Hewett et al., 2005; Briot et al., 2009). 
Spink5/ animals display a phenotype highly reminiscent of 
NS, replicating cutaneous and inflammatory aspects of the 
disease. Loss of LEKTI causes detachment of the SC from the 
underlying granular layer (GR) because of unopposed pro­
teolytic activity and premature degradation of desmosomes 
(Yang et al., 2004; Descargues et al., 2005). Keratinocyte 
hyperproliferation, abnormal distribution of differentiation 
markers, accelerated Flg degradation, and lipid defects are 
also evident (Descargues et al., 2005; Bonnart et al., 2010). 
Concurrently, uncontrolled proteolytic activity propagates acti­
vation of epidermal proinflammatory and proallergic signal­
ing pathways. In particular, proteolytic activation of PAR2 
results in elevated expression of the pro­Th2 cytokine, thymic 
stromal lymphopoietin (TSLP), as well as several other proin­
flammatory and proallergic mediators (Briot et al., 2009).
Despite the neonatal lethality of Spink5­deficient mice 
(Yang et al., 2004; Descargues et al., 2005; Hewett et al., 2005), 
considerable progress has been made on detailing the biologi­
cal pathways involved in NS pathophysiology. However, the 
significance of each protease implicated in the disease remains 
unclear. Loss of LEKTI leaves the activity of several proteases 
unopposed (Descargues et al., 2005; Deraison et al., 2007), 
many of which are capable of degrading desmosomes or filag­
grin, and stimulating inflammation. Protease activation cas­
cades present an additional layer of complexity by providing 
an avenue for proteases not targeted by LEKTI to be involved 
in NS, such as matriptase (Sales et al., 2010) and elastase­2 
(ELA2; Bonnart et al., 2010). These unknowns conceal the 
identity of the most promising pharmaceutical targets in NS 
and represent a major obstacle in developing targeted thera­
pies for NS and related skin disorders. Additionally, there is 
a current need to develop new animal models to study further 
aspects of NS pathophysiology, as Spink5/ mice uniformly 










Published February 17, 2014
JEM Vol. 211, No. 3 
Article
501
hair appeared thinner, lusterless, and spiky with flakes of dry 
skin on the fur. Cutting hair on the back revealed scaling un­
derneath the fur (Fig. 2 F, right). Additionally, vibrissae were 
reduced, disoriented, bent, and short at birth (Fig. 2 G). Con­
trary to body hair which showed a delay in growth but ap­
peared almost normal in nonlesional adult skin, whiskers 
stayed short and sparse as shown at 1 yr of age (Fig. 2 G). Fi­
nally, sub­cutaneous lumps were noticed around the neck and 
on the legs of Tg­KLK5 mice (arrow; Fig. 2 H). These cor­
responded to enlarged lymph nodes, which are examined in 
further detail below (see also Fig. 7).
hKLK5 expression triggers activation  
of the NS proteolytic cascade
In NS patients and Spink5­deficient mice, LEKTI defi­
ciency leads to unopposed activity of several proteases, in­
cluding KLK5, KLK7, and ELA2 (Descargues et al., 2005, 
2006; Bonnart et al., 2010). To study whether overexpression 
of KLK5 led to global changes in skin proteolytic activity, we 
next analyzed protein extracts of adult skin by casein gel 
zymography. Several bands of proteolytic activity were detected 
and found to be enhanced in Tg­KLK5 extracts (31, 28, 23, 
and 20 kD; Fig. 3 A). These bands have previously been iden­
tified as KLK5 (31 kD; Descargues et al., 2005), ELA2 (28 kD; 
Bonnart et al., 2010), and KLK7 (23–20 kD; Descargues et al., 
2005), whereas KLK14 has been shown to comigrate with 
KLK7 (Stefansson et al., 2006). These data confirmed that 
heterologous KLK5 was active in Tg­KLK5 epidermis and 
led to the activation of several additional protease targets.
To further explore the in vivo proteolytic activation cascade 
propagated by KLK5, we used peptide substrates known to 
be cleaved by downstream KLK proteases (KLK7 and KLK14; 
blue staining compared with WT, mainly located on the neck, 
abdomen, muzzle, and ears, suggesting that the skin barrier was 
defective (Fig. 2 B). To measure the extent of the skin barrier 
defect, we tested the ability of the skin to prevent fluid loss by 
measuring transepidermal water loss (TEWL). Tg­KLK5 neo­
nates showed significantly higher TEWL compared with wild­
type (Fig. 2 B).
During the first week of life, Tg­KLK5 mice remained 
smaller than WT littermates with reduced body weight 
(Fig. 2 C). They developed exfoliative erythroderma and scal­
ing of their entire body as shown at day 8 after birth in Fig. 2 
(C and D). Their hair growth was also delayed (Fig. 2, C and D). 
TEWL measurement revealed that the difference in barrier 
function between WT and Tg­KLK5 littermates had increased 
(Fig. 2 D). Although the severity of the phenotype was vari­
able among Tg­KLK5 littermates, growth delay, erythro­
derma, scaling, and sparse fur were observed in all animals at 
1 mo of age (Fig. 2 E). To examine this further, we analyzed 
disease severity using an adapted Netherton area severity as­
sessment (NASA) scheme which is used in the clinic for NS 
patients (Oji et al., 2005). Among Tg­KLK5 mice at 1 mo of 
age, extension of the lesions varied from localized on the head 
and trunk to more generalized lesions (head, trunk, back, and 
limbs). The severity of erythema varied between mild and 
severe, scaling between moderate and severe, and lichenifi­
cation (of the ears) between moderate and severe. Adult 
Tg­KLK5 mice showed normal size and body weight but 
developed intense and continuous scratching (varying from 
moderate to severe), resulting in chronic and extensive ero­
sions and crusts (Fig. 2 F, left). Another feature of NS is hair 
defects (brittle and sparse hair), which we could examine in 
Tg­KLK5 mice as they survive the neonatal period. Body 
Figure 1. Generation of transgenic- 
KLK5 mice. (A) Schematic structure of the  
transgene. The human full-length KLK5 cDNA 
was fused at its 3 end with the FLAG epi-
tope and cloned downstream of the regula-
tory sequences of the human IVL promoter. 
(B) Transgenic mice were discriminated from 
WT animals by genomic PCR using primers 
specific for the SV40 intron and the FLAG 
epitope (arrows in A). The Spink5 amplifica-
tion was used as internal control. Transgenic 
KLK5 expression was confirmed by Western 
blot analysis using (C) anti-KLK5 and (E) anti-
Flag antibodies on adult skin protein extracts. 
Localization of (D) KLK5 and (F) Flag expres-
sion by immunohistochemistry on adult WT 
and Tg-KLK5 skin sections. Inserts at the 
bottom right of panel (D) and (F) show  
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In situ zymography using BODIPY­FL­casein as a sub­
strate showed that epidermal proteolytic activity was confined 
to the SC in WT skin, and that this activity was increased 
and extended to the GR in Tg­KLK5 epidermis (Fig. 3 D). 
These results confirmed that heterologous KLK5 was active 
in the most differentiated layers of Tg­KLK5 epidermis. 
Using BODIPY­FL­elastin as a substrate for in situ zymog­
raphy, ELA activity was restricted to the GR and SC in WT 
epidermis, whereas it was slightly elevated and extended to 
suprabasal layers in Tg­KLK5 (Fig. 3 E). FITC­gelatin in situ 
zymography showed low activity in WT epidermis, whereas 
activity was considerably increased in the GR and SC of 
Tg­KLK5 (Fig. 3 F). In addition to increased proteolytic ac­
tivity in the epidermis of Tg­KLK5, caseinolytic, elastinolytic, 
de Veer et al., 2012, 2013). Cleavage of these substrates was 
elevated by more than twofold in Tg­KLK5 skin compared 
with WT (Fig. 3 B). Although we cannot entirely exclude 
substrate processing by other proteases, these results demon­
strate that both trypsin­ and chymotrypsin­like proteolytic 
activities are increased in Tg­KLK5 skin.
Changes in MMP activity were also analyzed using gela­
tin gel zymography. Two groups of bands were detected, the 
lowest band for each being at 62 (MMP2) and 92 kD (MMP9). 
Therefore, it appeared that MMP2 activity was slightly lower and 
MMP9 activity was enhanced in Tg­KLK5 samples (Fig. 3 C). 
The MW of these bands together with their sensitivity to 
EDTA identifies them as pro­, intermediate, and active forms 
of MMP2 and MMP9.
Figure 2. Phenotype of Tg-KLK5 mice 
combines a skin barrier defect, growth 
delay, hair abnormalities, and scratching 
lesions. (A) Transgenic and WT littermate 
and body weight at birth. (B) Skin barrier–
dependent dye exclusion assay using Tolu-
idine blue in Tg-KLK5 mice and WT littermate 
at birth and TEWL at birth. Mean TEWL value 
for WT was 9.3 g m2 h1 before normalization. 
Data from A–D are mean values ± SEM from 
at least 10 mice per genotype from 3 differ-
ent litters. P-values were calculated using 
the Mann-Whitney t test. **, P < 0.01 com-
paring genotypes as indicated. (C) Phenotype 
and body weight of Tg-KLK5 mice at day 8. 
(D) TEWL at day 8. Mean TEWL value for WT 
was 2.1 g m2 h1 before normalization. 
(E) Phenotype of Tg-KLK5 mice at 1 mo of 
age. Tg-KLK5 mice show a substantial but 
transient growth delay, erythroderma, scal-
ing of the body and alopecia of the back, 
front, and head. (F) Phenotype at 1 yr of age. 
Persistent scratching leads to alopecic, 
erosive, and crusty injuries (F, left). Nonle-
sional skin shows scaling underneath the fur 
(right). (G) Whiskers aspects at birth (G, left) 
and in adults (G, right). (H) Swelling of re-
gional lymph nodes (arrowhead) of Tg-KLK5 
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(Fig. 4 A, bottom). On electron microscopy sections, abnormal 
detachment of cells was evident in Tg­KLK5 epidermis. Ultra­
structural analysis showed that desmosomes were not cohesive 
at the interface between the GR and SC (Fig. 4 B). These 
structures were asymmetrically split with both dense plaques 
staying assembled. Contrary to Spink5/ skin in which many 
remnant nuclei and keratohyalin granules were observed in 
corneocytes (Descargues et al., 2005), only mild parakeratosis, 
and no keratohyalin granules in the SC were observed after 
histological or electron microscopy analyses (Fig. 4 A).
Several studies have shown that KLK5 is able to degrade 
desmoglein­1 (Dsg­1) and desmocollin­1 (Dsc­1) in vitro, 
and therefore is regarded to contribute to the detachment of 
superficial corneocytes during desquamation (Suzuki et al., 
1993; Brattsand and Egelrud, 1999; Caubet et al., 2004). We 
next analyzed the expression of the major desmosomal com­
ponents including Dsg­1, Dsc­1, and desmoplakin (Dsp). Im­
munostainings against Dsg­1 and Dsc­1 on WT epidermal 
and gelatinolytic activities were also increased in the dermis 
of these animals (Fig. 3, D–F). Overall, these data show that 
expression of hKLK5 in the GR of Tg­KLK5 mice is suffi­
cient to enhance KLK7, KLK14, and ELA2 activities in the 
epidermis, identifying KLK5 as an important contributor to 
the NS proteolytic cascade.
KLK5 hyperactivity causes SC detachment  
through desmosome cleavage
NS patient skin shows characteristic acanthosis, hyperkerato­
sis, and SC detachment at the interface with the GR through 
desmosomal degradation. Histological analysis of Tg­KLK5 
epidermis revealed intercellular separation at the GR­SC 
boundary and detachment of the SC from the GR (Fig. 4 A, 
top). Compared with WT, Tg­KLK5 epidermis constantly 
showed marked acanthosis, papillomatosis and hyperkeratosis 
before SC detachment. Interestingly, hair follicles were sig­
nificantly reduced in number, hyperplastic and disorganized 
Figure 3. KLK5 overexpression dysregu-
lates an epidermal protease activation 
cascade. (A) Proteolytic activity in skin 
extracts from WT and Tg-KLK5 mice was ex-
amined by gel zymography using casein as an 
in-gel substrate. Areas of proteolytic activity 
are visible as clear bands against a dark back-
ground. The experiment shown is representa-
tive of five performed with three animals of 
each genotype. (B) Changes in proteolytic 
activity using a series of colorimetric sub-
strates that target different proteases. Activity 
in WT and Tg-KLK5 extracts was detected by 
measuring absorbance at 405 nm after over-
night incubation with substrates for either 
tryptic proteases (KLK5, KLK14, and matrip-
tase), KLK7 or KLK14. Data are shown as the 
mean ± SEM of duplicates for four mice per 
genotype. The experiment shown is represen-
tative of three. P-values were calculated using 
the Mann-Whitney t test. **, P < 0.01 and  
***, P < 0.001 comparing genotypes as indicated. 
(C) Gel zymography using gelatin as an in-gel 
substrate. The experiment shown is represen-
tative of five performed with three animals of 
each genotype. (D–F) The localization of pro-
teolytic activity was analyzed by in situ  
zymography on cryosections of WT and  
Tg-KLK5 skin using internally quenched protein 
substrates. Cryosections were incubated with 
(D) BODIPY FL casein, (E) BODIPY FL elastin, or 
(F) FITC gelatin overnight and images were 
acquired using a Leica SP5 confocal laser 
scanning microscope. Fluorescence intensity 
data were transformed to a color gradient  
(as depicted) using ImageJ software. Dashed 
white lines represent the dermal–epidermal 
junction. The results shown are representative 
of experiments performed on at least five 
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sections revealed labeling limited to the cell border in the 
upper epidermis. In Tg­KLK5 epidermis, cell dissociation 
correlated with a marked reduction of Dsg­1 and Dsc­1 stain­
ings in suprabasal epidermis compared with WT (Fig. 4, 
C and F). Western blot analysis confirmed a lower amount of 
Dsg­1 in epidermal extracts from Tg­KLK5 mice (Fig. 4 D). 
Transcript levels of Dsg-1 analyzed by quantitative RT­PCR 
were not reduced in Tg­KLK5 compared with WT mice, 
supporting the notion that reduced Dsg­1 expression resulted 
from proteolytic degradation (Fig. 4 E). In Spink5/ mice, as 
well as in NS patients, we have previously shown that increased 
proteolytic activity leads to SC detachment at the GR–SC 
interface through degradation of Dsg­1, Dsc­1, and Dsp 
(Descargues et al., 2005, 2006). However, in Tg­KLK5 epi­
dermis, Dsp was not affected by KLK5 hyperactivity (unpub­
lished data). Altogether, these data provide in vivo evidence 
that KLK5 hyperactivity initiates desmosomal component deg­
radation and detachment of the SC from the GR.
Tg-KLK5 mice show no evidence for abnormal  
epidermal terminal differentiation
In addition to premature desquamation, NS skin shows impaired 
terminal differentiation with lipid abnormalities (Descargues 
et al., 2005, 2006; Bonnart et al., 2010). We next investigated 
epidermal terminal differentiation markers including involu­
crin, loricrin, and Flg in the epidermis of Tg­KLK5 mice. In­
volucrin, which is an early marker of cornification, was 
expressed in the upper spinous layer and in the GR of WT 
epidermis (Fig. 5 A). In Tg­KLK5 epidermis, involucrin 
showed the same pattern of expression but appeared to be 
extended due to acanthosis (Fig. 5 A). Immunostaining of 
loricrin, a later marker of cornification, was restricted to the 
upper GR and was not different between WT and Tg­KLK5 
(Fig. 5 B). Flg, which is mainly present in the GR and SC 
of WT epidermis, showed the same pattern of expression in 
Tg­KLK5 epidermis (Fig. 5 C), unlike Flg over­degradation 
in Spink5/ and Tg­ELA2 epidermis (Descargues et al., 
2005; Bonnart et al., 2010). By Western blot analysis, no dif­
ference could be detected in Flg processing between WT and 
Tg­KLK5 (Fig. 5 D). We conclude that the skin barrier defect 
in Tg­KLK5 mice is not associated with an abnormal differ­
entiation pattern.
In adult WT and Tg­KLK5 epidermis, nile red staining 
revealed uniform, linear lipophilic structures corresponding 
to corneocyte intercellular spaces. In WT, staining was thin 
and corresponded to the SC. In Tg­KLK5, multiple layers 
were seen, corresponding to hyperkeratosis (Fig. 5 E). Con­
trary to Spink5/ and Tg­ELA2 skin, no lipid droplets were 
observed in Tg­KLK5. Oil Red O, specific for free fatty acids, 
triglycerides, and esterified cholesterol showed staining only 
Figure 4. SC detachment is a result of hyperactive hKLK5 and 
degradation of desmosomal components. (A) Hematoxylin/eosin/safranin 
(HES) staining of adult WT and Tg-KLK5 skin sections. Bar, 25 µm (top); 
250 µm (bottom). (B) Ultrastructural analysis showing asymmetrical des-
mosome splits at the GR-cornified interface in Tg-KLK5 epidermis (arrowhead). 
Bar, 200 nm. (C) Immunohistochemical analysis of desmoglein-1 (Dsg-1) 
expression in WT and Tg-KLK5 skin sections. Bar, 25 µm. (D) Western blot 
analysis of Dsg-1 in Tg-KLK5 epidermis compared with WT epidermis. 
Inserts at the bottom right show immunostaining with isotype control. 
(E) Quantitative RT-PCR of Dsg-1 relative to Hprt on mRNA extracted 
from Tg-KLK5 and WT skin. Data are shown as the mean ± SEM of tripli-
cate amplification for four mice per genotype. The experiment was  
performed three times. (F) Immunohistochemical analysis of desmocollin-1 
(Dsc-1) expression in WT and Tg-KLK5 skin sections. Bar, 25 µm. The  
immunohistochemistry and histology results shown are representative  
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results demonstrate that KLK5 overexpression does not alter 
terminal differentiation reflected by differentiation marker 
expression or lipid abnormalities.
KLK5 hyperactivity leads to cutaneous signs  
of allergy and inflammation
Uncontrolled proteolytic activity in NS leads to persistent ac­
tivation of inflammatory signaling pathways in the epidermis. 
In NS epidermis, we previously uncovered a cell­autonomous 
process in which KLK5 directly activates PAR2 and induces 
NF­B–mediated overexpression of thymic­stromal lympho­
poietin (TSLP), intracellular adhesion molecule (ICAM­1), 
TNF, and IL­8 (Briot et al., 2009). Furthermore, Spink5/­
grafted skin is rich with proinflammatory and proallergic 
in the SC for both WT and Tg­KLK5 animals with no ab­
normal deposition in the skin (Fig. 5 F). Filipin, specific for 
unesterified cholesterol, intensely stained the SC in both WT 
and Tg­KLK5 animals (Fig. 5 F). Increased intensity of staining 
in Tg­KLK5 for Oil Red O and filipin could be attributable 
to marked hyperkeratosis (Fig. 5, F and G).
As epidermal lipid composition analysis requires isolation 
of the epidermis from the dermis, we used skin samples from 
8­d­old mice, before hair emerges from the skin, for high 
performance­thin layer chromatography (HP­TLC). At this 
stage of analysis, hyperkeratosis is not as pronounced as in 
adult skin. No difference in lipid composition for triglycer­
ides, free fatty acids, cholesterol, and ceramides was observed 
between WT and Tg­KLK5 at day 8 (Fig. 5 H). Overall, these 
Figure 5. Tg-KLK5 skin does not show evidence of abnormal epidermal differentiation. The expression of late-stage differentiation markers in-
volucrin (A), loricrin (B), and Flg (C) was examined in paraffin-embedded skin sections from WT and Tg-KLK5 (Tg) mice by immunohistochemistry. The 
inset on each panel shows the isotype control for each staining. Bar, 25 µm. The results shown are representative of experiments performed on at least 
five animals of each genotype. (D) Immunodetection of pro-Flg, Flg, and Flg-processing intermediate dimers (2xFlg) and trimers (3xFlg) in epidermal ex-
tract from an 8-d-old WT and Tg-KLK5 animals and newborn Spink5/. The experiment was performed three times with two animals of each genotype. 
The distribution of different lipid subsets was analyzed by staining with nile red (total lipids; E), Oil Red O (neutral lipids; F), and filipin (unesterified cho-
lesterol; G). Fluorescence intensity data from filipin staining was transformed to a color gradient (as depicted) using ImageJ software. The results shown 
are representative of experiments performed on at least five animals of each genotype. Bar, 10 µm (E); 25 µm (F and G). (H) HP-TLC of lipids extracted 
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(Fig. 6 F). CCL17/TARC and CCL22/MDC are major pro­
Th2 mediators that can recruit proallergic Th2 cells via the 
chemokine receptor CCR4 to the skin (Homey and Zlotnik, 
1999). In Tg­KLK5 skin, Ccl17 and Ccl22 mRNA levels 
showed a slight increase (Fig. 6 F). In contrast, Ccl8 (known 
to attract actors of allergy and inflammation) and Ccl20 
(a chemoattractant for Th17 cells) showed significantly ele­
vated expression in Tg­KLK5 skin (Fig. 6 F). In addition, 
Tg­KLK5 skin showed elevated expression of Il­6, Il­18, 
and Il­23 (Fig. 6 G).
Among the allergy/atopy­associated Th1/Th2 and Th17/
Th22 cytokines, Il­4, Il­17, and Il­22 mRNA levels showed a 
significant increase in the skin of Tg­KLK5 mice (Fig. 6 H). 
Additionally, genes known to be up­regulated by Th17 such 
as Defb4 and Cxcl1 (Nograles et al., 2008) showed elevated 
expression at the mRNA level in Tg­KLK5 skin (Fig. 6 I). 
IL­17 and IL­22 are known to up­regulate the expression 
of S100A7, S100A8, and S100A9 in human keratinocytes 
(Boniface et al., 2005; Nograles et al., 2008). Increased levels 
molecules and is highly infiltrated by activated mast cells and 
eosinophils (Briot et al., 2009). Tg­KLK5 nonlesional skin re­
produced similar abnormalities, including infiltrates of T cells, 
mast cells and presence of eosinophil granulocytes in the der­
mis whereas none could be seen in WT (Fig. 6, A–C).
Disruption of the epidermal barrier stimulates elevated 
expression of an array of proinflammatory cytokines and 
activates signaling pathways that modulate keratinocyte differ­
entiation and the immune response. To profile the proinflam­
matory environment induced by KLK5 hyperactivity, we 
performed a targeted transcript analysis using qRT­PCR. 
First, we examined the expression of prominent proinflam­
matory and proallergic cytokines in WT and Tg­KLK5 non­
lesional skin. Expression of the pro­Th2 cytokine Tslp, was 
significantly increased in Tg­KLK5 skin, both at the mRNA 
and protein level (Fig. 6, D and E). Additionally, Tnf­, Il­1, 
and Icam­1 were all significantly increased at the mRNA 
level (Fig. 6 E). We next investigated the expression of mole­
cules which are known to attract immune cells to the skin 
Figure 6. Proallergic and inflammatory 
signals in Tg-KLK5 nonlesional skin.  
(A) Toluidine blue staining to detect infiltra-
tion of mast cells (stained purple). Bar, 100 µm. 
(B) Luna staining to detect polynuclear  
eosinophilic cells in adult nonlesional skin. 
Bar, 25 µm. (C) Immunohistochemical analysis 
of CD3+ cells in adult nonlesional skin sec-
tions (arrows). Bar, 100 µm. (D) Immunohisto-
chemical analysis of TSLP expression in adult 
WT and nonlesional Tg-KLK5 skin. Bar, 25 µm. 
Insets at the bottom right show isotype con-
trols. Stainings are representative of experi-
ments performed three times with five 
animals of each genotype. (E–I) Relative 
mRNA expression of proinflammatory and 
proallergic cytokines and chemokines ana-
lyzed by quantitative RT-PCR on RNA ex-
tracted from adult nonlesional Tg-KLK5 skin 
and WT skin. Data are shown as the mean ± 
SEM of triplicate amplification for at least six 
mice per genotype. Results are normalized to 
WT mean (set as 1.0). P-values were calculated 
using the Mann-Whitney t test. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001. The experiment 
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display key features of NS but die shortly after birth (Yang 
et al., 2004; Descargues et al., 2005; Hewett et al., 2005). Here, 
we developed a new model of NS by overexpressing KLK5 in 
the epidermis. These mice allowed us to both decipher the 
role of KLK5 hyperactivity in NS pathogenesis in vivo, and 
to provide a new and viable model to study further aspects of 
NS physiopathology, particularly those that become promi­
nent after birth. We provide evidence here that overexpression 
of KLK5 in the epidermis leads to the development of the 
major NS hallmarks, confirming the role of KLK5 as a key 
contributor to the NS proteolytic cascade. In addition, we 
provide a new and viable mouse model recapitulating the 
hallmarks of NS.
In NS, the absence of LEKTI has been shown to result 
in unopposed activity of several proteases (Descargues et al., 
2005, 2006; Bonnart et al., 2010). We show here that over­
expression of human KLK5 in murine epidermis triggers 
major enhancement of the global proteolytic activity in the 
skin that overcomes the inhibitory capacities of Lekti. As our 
construct expresses KLK5 as a proprotease, this implies that 
it has been activated in vivo. It has recently been shown that 
matriptase can activate pro­KLK5 and pro­KLK7 in vitro 
(Sales et al., 2010). KLK5 has been shown to activate pro­
KLK7, pro­KLK14, and pro­ELA2, as well as to amplify cas­
cade initiation by activating pro­KLK5 in vitro (Brattsand 
et al., 2005; Bonnart et al., 2010). Using gel zymography and 
peptide substrates, we have shown that not only KLK5 activ­
ity but also KLK7, KLK14, and ELA2 activities were increased 
in Tg­KLK5 skin. These results provide in vivo evidence that 
KLK5 can indeed activate KLK7, KLK14, and ELA2 as 
described by in vitro experiments (Brattsand et al., 2005; 
Bonnart et al., 2010). In addition, we observed an increase in 
MMP9 activity in Tg­KLK5 skin. It is to our knowledge 
the first description of a functional link between MMP9 and 
KLK5, which is potentially mediated by PAR2 activation as 
demonstrated in transgenic CAP1/Prss8 Par2­deficient mice 
(Frateschi et al., 2011).
NS patients suffer from a profound skin barrier defect. 
Histopathologic examination of NS skin reveals a psoriasi­
form epidermis, associated with hyperkeratosis, hyperplasia of 
the subcorneal epithelium (acanthosis), and varying degrees 
of epidermal invaginations into the dermis (papillomatosis; 
Hausser and Anton­Lamprecht, 1996). These observations are 
consistent with the fact that skin barrier defects can induce 
compensatory hyperproliferative mechanisms resulting in 
hyperkeratosis and acanthosis. Another feature of NS epidermis 
is premature detachment of the SC from the GR as a result of 
desmosome cleavage (Descargues et al., 2005, 2006). These 
features are all seen in Tg­KLK5 skin, including marked acan­
thosis, papillomatosis, and hyperkeratosis before SC detach­
ment. Interestingly, IL­22, which is increased in chronic stages 
of atopic dermatitis induces epidermal hyperplasia (Nograles 
et al., 2008). The increased Il­22 expression observed in Tg­
KLK5 skin could thus contribute to acanthosis. In Tg­KLK5 
skin, the SC detachment occurs at the SC–GR interface as 
a result of desmosome cleavage through Dsg­1 and Dsc­1 
of Il­17 and Il­22 transcripts in Tg­KLK5 skin coincided with 
significant increases in S100a7, S100a8, and S100a9 mRNA 
expression (Fig. 6 I). Finally, the expression of genes up­regulated 
by Th1/IFN­ such as Ccl5, Cxcl9, Cxcl10, and Cxcl11 were 
all considerably reduced in Tg­KLK5 skin (Fig. 6 I).
Collectively, these data demonstrate that dysregulated 
KLK5 activity in the skin is sufficient to induce cutaneous 
allergic inflammation. This involves up­regulation of Tslp, 
Icam­1, and Tnf­ and the production of chemokines known 
to attract mast cells, eosinophil granulocytes, and Th2/Th17/
Th22 cells involved in allergy and inflammation.
KLK5 hyperactivity triggers systemic  
allergy and inflammation
NS is a severe disease that is associated with a broad spectrum 
of severe atopic manifestations with high IgE levels. TSLP has 
been shown to be elevated in the serum of children with 
atopic dermatitis (Lee et al., 2010). Increased Tslp expression 
in Tg­KLK5 skin led us to investigate the expression of this 
major pro­Th2 cytokine in the serum of adult Tg­KLK5 
mice. Tslp levels were significantly elevated in the serum of 
Tg­KLK5 as compared with WT mice (Fig. 7 A). Addition­
ally, we found significantly increased levels of total IgE in 
Tg­KLK5 serum, and elevated total IgG, mainly due to in­
creased IgG1 (Fig. 7 B). We next examined the morphology 
of lymphoid tissues including the spleen, thymus, and draining 
lymph nodes (cervical and inguinal). The spleen and lymph 
nodes were enlarged in Tg­KLK5 mice, whereas the thymus 
appeared slightly smaller (Fig. 7 C). Lymph node enlargement 
resulted from hyperplasia as shown by the increase in the 
number of cells in inguinal nodes (Fig. 7 D).
The pro­Th2 cytokine TSLP, which is highly expressed in 
the skin and the serum of Tg­KLK5 mice, is known to induce 
a proallergic microenvironment and to promote the differ­
entiation of T helper (Th) 0 cells into proallergic Th2 cells 
(Soumelis et al., 2002). This led us to investigate whether 
T cells isolated from lymph nodes were Th1, Th2, and/or 
Th17 biased in Tg­KLK5. Phenotyping the cell populations 
from draining lymph nodes revealed an increased number of 
B cells, monocytes, dendritic cells, and T lymphocytes (unpub­
lished data). Of the CD4+ T cells isolated from lymph nodes, 
a higher proportion were IL­4+, IL­13+, TNF­+, and IL­17+–
producing T cells as compared with WT (Fig. 7 E). Collectively, 
these data establish that the effects of KLK5 hyperactivity are 
not restricted to the skin. Indeed, overexpression of the pro­
tease specifically in the epidermis led to the production of 
allergy markers found in the serum and to the expansion of 
activated T cells in draining lymph nodes, as a consequence of 
skin inflammation and allergy.
DISCUSSION
Netherton syndrome (NS) is a rare autosomal recessive skin 
disease with severe skin inflammation and scaling, a specific 
hair shaft defect and constant allergic manifestations. We and 










Published February 17, 2014
508 Transgenic KLK5 mice recapitulate features of Netherton syndrome | Furio et al.
not observe major alterations in either epidermal terminal 
differentiation or Flg processing in Tg­KLK5 mice, even 
though ELA2 activity was increased. One possibility could 
be that ELA2 activity did not reach the level of activation 
observed in the Tg­ELA2 murine model as suggested by 
comparative elastin in situ zymography between Tg­ELA2 
and Tg­KLK5 (unpublished data). Consistent with this, kera­
tohyalin granules in Tg­KLK5 were still present, in contrast to 
Tg­ELA2 where they were absent (Bonnart et al., 2010). Re­
cently, KLK5 was shown to directly process pro­Flg in vitro 
degradation as previously demonstrated in NS skin (Descargues 
et al., 2005, 2006). NS skin also exhibits impaired epidermal 
differentiation, with increased involucrin and loricrin expres­
sion, fewer keratohyalin granules, decreased Flg immuno­
staining in the GR and abnormal lipid structure and composition 
(Descargues et al., 2005, 2006; Bonnart et al., 2010). We 
have previously shown that ELA2 is hyperactive in NS skin 
and that transgenic mice overexpressing ELA2 in the GR 
displayed abnormal (pro­) Flg processing and impaired lipid 
lamellae structure (Bonnart et al., 2010). Of note, we did 
Figure 7. Proallergic systemic inflammation in Tg-KLK5 mice. (A) Serum TSLP levels in WT and Tg-KLK5 mice. Results shown are from at least  
6 mice of each genotype. P-values were calculated using the Mann-Whitney t test. ***, P < 0.001. (B) IgE, IgG, IgG1, and IgG2 levels in the serum of adult 
mice. Results shown are from at least six mice of each genotype. **, P < 0.01; ***, P < 0.001. (C) Macroscopic appearance of inguinal and cervical lymph 
nodes (left), spleen (right), and thymus (right) in WT and Tg-KLK5 adult mice. (D) Number of cells per inguinal lymph node in adult mice. Values corre-
spond to mean ± SEM from nine animals per genotype. ***, P < 0.001. (E) Analysis of cytokine secretion from CD4 T cells after stimulation with PMA and 
ionomycin. Proportion of cells producing IL-4, IL-13, TNF-, and IL-17 among the CD4 T cell population. Representative dot plots are shown. Values in the 
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Spink5/ skin grafts (Briot et al., 2009). These features of se­
vere cutaneous inflammatory and atopic manifestations are 
prominent in Tg­KLK5 mice. Our results establish that KLK5 
overactivity in murine epidermis is sufficient to induce a pro­
allergic and proinflammatory environment.
In skin of atopic dermatitis patients, TSLP expression is 
associated with the migration of Langerhans cells to the 
draining lymph nodes. TSLP­activated dendritic cells have 
been shown to induce naive T cells to differentiate into 
“allergic” Th2 cells producing IL­4, IL­5, IL­13, and TNF 
(Soumelis et al., 2002). We have previously shown that NS 
keratinocytes show high expression of TSLP (Briot et al., 
2009). Consistent with this observation, we showed that 
TSLP expression was also strongly enhanced in Tg­KLK5 skin. 
Normal human keratinocytes do not express detectable levels 
of TARC and MDC, contrary to NS and AD keratinocytes 
(Horikawa et al., 2002; Tsuda et al., 2003; Briot et al., 2009). 
These two chemokines can recruit Th2 cells via CCR4 to the 
skin, defining them as major pro­Th2 mediators (Homey and 
Zlotnik, 1999). In NS keratinocytes, we have previously 
shown that MDC and TARC are not induced by KLK5 and 
PAR2 activation (Briot et al., 2009). We have confirmed this 
observation in vivo because Tg­KLK5 skin exhibits only a 
slight increase of these two chemokines. However, the pres­
ence of IL­4 in Tg­KLK5 skin reflects the presence of Th2 
cells. This suggests that slightly elevated Mdc and Tarc levels, 
when combined with the inflammatory environment are 
sufficient to recruit Th2 cells to the skin of Tg­KLK5 mice.
We also uncovered the presence of Th17 and Th22 cells in 
Tg­KLK5 skin. In inflammatory diseases, such as psoriasis, it 
has been shown that the presence of “inflammasome related” 
cytokines such as IL­1 and IL­18 could synergize with 
IL­23 to promote Th17 cell differentiation (Mills et al., 2013). 
In Tg­KLK5 skin, we found elevated expression of Il­1, 
Il­18, and Il­23, which could explain the presence of Th17 
cells. The treatment of healthy keratinocytes with TNF in­
duces the expression of CCL20, a molecule involved in Th17 
recruitment (Kennedy­Crispin et al., 2012). It is thus possible 
that enhanced Tnf­ and Il­1 production in Tg­KLK5 con­
tributes to Ccl20 expression leading to Th17 recruitment. Of 
note, IL­17 has been shown to induce the secretion of pro­
inflammatory cytokines (IL­1 and IL­6), antimicrobial pep­
tides, and several chemokines including IL­8 and CCL20 in 
human keratinocytes. In addition, the induction of CCL20 
by keratinocytes has been suggested as a mechanism that 
maintains Th17 cells in skin (Perera et al., 2012). We have also 
found increased expression of Defb4, Cxcl1, S100a7, S100a8, 
and S100a9 in Tg­KLK5 skin, which are genes known to be 
induced by Il­17 and Il­22. A similar inflammatory profile is 
found in atopic dermatitis in which, in addition to Th2, Th22 
and Th17 play important roles in the pathogenesis of the dis­
ease (Guttman­Yassky et al., 2013; Suárez­Fariñas et al., 2013). 
These observations support the contribution of Th17 and Th22 
cells to skin inflammation in the Tg­KLK5 murine model.
Unlike Spink5/ mice, Tg­KLK5 mice are viable, which 
allowed us to investigate signs of allergy in the serum. We 
(Sakabe et al., 2013). The fact that no significant decrease in 
pro­Flg was observed in Tg­KLK5 animals suggests that regu­
lation of pro­Flg processing by KLK5 is more complex and 
involves additional factors in vivo. The presence of Lekti in 
Tg­KLK5 mice could imply that KLK5 and other pro­Flg 
processing proteases, such as caspase 14, remained sufficiently 
regulated during terminal differentiation to prevent Flg over­
degradation. The observation that Tg­KLK5 mice reproduce 
major abnormalities of NS supports an important role for 
KLK5 in the disease. However, not all features are observed, 
suggesting that additional proteases could be involved in the 
complete phenotype.
NS patients show failure to thrive in infancy and short 
stature. In a similar way, Tg­KLK5 mice displayed a lower 
weight at birth and a growth delay. However, this delay was 
only transient and mice had a nearly normal weight and size 
at 2 mo of age. Several KLKs, including KLK5, are known to 
cleave growth hormone (GH) and to be present in the pitu­
itary gland (Komatsu et al., 2007). It has been suggested that 
in NS patients the absence of LEKTI leads to higher proteo­
lytic processing of GH, which may become biologically inac­
tive (Komatsu et al., 2007). As we do not expect transgene 
expression in the pituitary gland and Lekti is still present in 
Tg­KLK5, it is possible that other factors contribute to the 
growth delay in Tg­KLK5 mice. Another characteristic fea­
ture of NS patients is a specific hair shaft defect (trichor­
rhexis invaginata) that leads to sparse, brittle, and spiky hair. In 
Tg­KLK5 animals, we observed an apparent thinning of body 
hair, which had a lusterless and spiky appearance. As in new­
born Spink5/ mice (Descargues et al., 2005), Tg­KLK5 whis­
kers were scarce, disoriented, bent, and short. Existing murine 
models such as Cathepsin L/ or Matriptase/ have shown 
that hair follicle morphogenesis is a protease­dependent pro­
cess (Roth et al., 2000; List et al., 2002). This viable murine 
model will allow the mechanisms underlying hair follicle ab­
normalities in NS to be deciphered.
In NS patients, atopic features with elevated IgE are con­
stant during infancy and adulthood. These include eczematous­
like lesions, allergic asthma, allergic rhinitis, urticaria, and 
angiodema (Sun and Linden, 2006). Only a few immunologi­
cal studies have been reported in NS patients to date (Judge 
et al., 1994; Stryk et al., 1999; Renner et al., 2009). In these 
studies, a constant finding is elevated specific IgE levels to 
common allergens, although a proallergic Th2 skew has not 
been consistently found. Studies on Spink5/ skin have been 
limited to grafting experiments on WT mice and have shown 
enhanced expression of proinflammatory cytokines, such as 
Il­1, Tnf­, IL­8, and Icam­1 and proallergic mediators, 
such as Tslp, Ccl17 (Tarc), and Ccl22 (Mdc; Briot et al., 2009). 
We have previously shown that increased TNF, IL­8, ICAM­1, 
and TSLP expression is an intrinsic property of NS kera­
tinocytes as a result of the KLK5–PAR2–NF­B pathway 
(Briot et al., 2009). The proinflammatory and proallergic cy­
tokines overexpressed in NS epidermis play an active role in 
recruiting inflammatory cells to the skin, including mast cells 
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Committee on Standardized Genetic Nomenclature for Mice. Transgenic 
mice were named Tg­KLK5 for the following study.
TEWL measurement. TEWL was measured using an EP1 evaporimeter 
(ServoMed) as previously described (Descargues et al., 2005).
Barrier function assay. Euthanized newborn mice were immediately sub­
jected to graded methanol dehydration and subsequent rehydration as pre­
viously described (Ekholm et al., 2000). Pups were then washed in PBS for 
1 min, stained in 0.1% toluidine blue (Sigma­Aldrich) for 1 h at room tem­
perature, destained for 15 min in PBS, and analyzed.
RNA isolation, RT, and quantitative real-time PCR. Murine skin was 
crushed in RLT buffer (QIAGEN) using an Ultra­Turax, after which RNA 
was isolated using the RNeasy mini kit (QIAGEN). Complementary DNA was 
synthesized by reverse transcription from 1 µg total RNA using M­MLV Re­
verse transcription (Invitrogen). Quantitative real­time PCR was performed on 
an ABI prism 7500 Sequence Detection system (Applied Biosystems) using 
qPCR MesaGreen Mastermix (Eurogentec). The expression of target genes was 
normalized to murine hypoxanthine phosphoribosyl transferase (Hprt). Primer 
sequences can be obtained on request from the authors. Data were analyzed 
using 7500 software v2.0.6. (Applied Biosystems).
Antibodies. Antibodies used for Western blot analysis and immunohisto­
chemistry were: Actin (A5441; Sigma­Aldrich), Flag (F7425; Sigma­Aldrich); 
Desmocollin­1 (sc18115; Santa Cruz Biotechnology, Inc.); Desmoglein­1 
(sc20114; Santa Cruz Biotechnology, Inc.); Flg (PRB­417P; Covance); KLK5 
(ab7283; Abcam); Involucrin (sc15230; Santa Cruz Biotechnology, Inc.); 
Loricrin (PRB­145P; Covance); TSLP (AF555; R&D Systems); and CD3 
(ab5690; Abcam).
Western blotting. For Western blot analysis, skin was crushed in protein 
extraction buffer (50 mM Tris­HCl, pH 8.5, 5 mM EDTA, 150 mM NaCl, 
0.1% Nonidet­P40, and Protease Inhibitor Cocktail Tablets [Complete, Roche]) 
using an Ultra­Turax. Lysates were clarified by centrifugation (13,000 g, 4°C 
for 30 min) to remove insoluble material. For Flg Western blot analysis, pro­
teins were extracted using 50 mM Tris­HCl, pH 8.0, 8 M urea, 10 mM 
EDTA, and Protease Inhibitor Cocktail Tablets. Protein content in each sam­
ple was measured by Bradford assay (Bio­Rad Laboratories) according to the 
manufacturer’s instructions. Protein fractions were mixed with Laemmli buf­
fer, incubated for 5 min at 90°C, and then separated by SDS­PAGE. For 
KLK5, Flag, and Dsg­1 Western blots, 5 µg of proteins (for Flg, 1.5 µg of proteins) 
were loaded on a 4–12% precast gel (Invitrogen). After migration, proteins 
were transferred to Hybond­ECL membranes (GE Healthcare). After incu­
bation with primary and secondary antibodies, enhanced chemiluminescence 
detection was performed as recommended by the manufacturer (Thermo 
Fischer Scientific).
In situ zymography. Skin cryosections (5­µm thickness) were mounted 
on glass slides, rinsed with 2% Tween 20 in PBS and incubated at 37°C over­
night with 10 µg ml1 BODIPY FL casein (Life Technologies), 100 µg ml1 
BODIPY FL elastin (Life Technologies) or 4 µg ml1 FITC­gelatin (Life 
Technologies) in 50 mM Tris­HCl, pH 8.0. Sections were rinsed with PBS 
and visualized using a Leica TCS SP5 AOBS confocal microscope. Data were 
analyzed using ImageJ (National Institutes of Health) software.
Proteolytic activity assays. For proteolytic activity assays, skin was 
crushed in 1 M acetic acid using an Ultra­Turax. After overnight extraction 
at 4°C, insoluble material was removed by centrifugation (13,000 g, 4°C for 
30 min) and the supernatant was dried using a Speed­Vac. Proteins were 
resuspended in water overnight at 4°C and clarified by centrifugation (13,000 g, 
4°C for 30 min). Protein content was determined by Bradford assay 
(Bio­Rad Laboratories).
For gel zymography, 10 µg of protein extracts were loaded onto casein/
acrylamide copolymerized gels (15% acrylamide, 0.1% ­casein; Sigma­Aldrich) 
found elevated Tslp and IgE concentrations that reflect the 
Th2 cytokine­mediated IgE class switch of B cells. Thus, our 
results show that the effects of dysregulated KLK5 activity 
are not restricted to Tg­KLK5 skin. In Tg­KLK5 mice, con­
tinuous scratching led to alopecic, erosive, and crusty skin le­
sions. These observations are highly relevant to NS patients 
who show constant, often severe and disabling pruritus. Per­
sistent itch causes sleeplessness and scratching, which further 
aggravate skin lesions. A well­established mediator of itching 
is PAR2 activation (Steinhoff et al., 2003). Several serine pro­
teases capable of activating PAR2 are present in Tg­KLK5 
skin, including KLK5, KLK14 in the epidermis, and tryptase 
from infiltrating mast cells. Tg­CAP1/Prss8 mice display a 
similar itchy phenotype, which could be rescued by PAR2 
knock­down (Frateschi et al., 2011). In Tg­KLK7 mice, which 
develop chronic dermatitis, itching does not respond to anti­
histamine therapy and is also potentially attributable to PAR2 
activation (Hansson et al., 2002).
In summary, we have generated a new and viable murine 
model that recapitulates the major cutaneous and systemic 
hallmarks of NS and validates KLK5 as a promising target for 
NS treatment. Accordingly, successful inhibition of KLK5 
has the potential to reduce the skin barrier defect as well as 
features of inflammation and allergy. Furthermore, this model 
will allow the study of further aspects of NS pathophysiology 
that are currently not well understood, such as growth delay, 
immune system dysregulation, and hair defects. It will also be 
instrumental for preclinical testing of therapies for NS and 
related diseases that involve a skin barrier defect and severe 
atopic manifestations. Indeed, atopic dermatitis shows several 
similarities with NS, including increased skin barrier permea­
bility and elevated TSLP, which lead to a Th2­biased response 
and high serum IgE. Collectively, our results show that the 
Tg­KLK5 murine model shares important similarities with 
human atopic dermatitis. Therapies aiming at controlling 
these dysregulated pathways could be evaluated in vivo using 
the Tg­KLK5 murine model.
MATERIALS AND METHODS
Generation of KLK5 transgenic mice. This work was approved by the 
Commission de Génie Génétique (01–10­08, agreement number 4858) and 
all experiments were performed in accordance with the required guidelines 
and regulations. The full­length cDNA encoding human KLK5 (I.M.A.G.E. 
clone 100020682) was amplified by RT­PCR. The FLAG octopeptide epi­
tope was added to the 3 end of the resulting product followed by NotI 
restriction sites to both ends. After digestion with NotI, this construct was 
inserted into the IVL promoter vector (pH3700­pL2; gift from J. Segre, 
National Human Genome Research Institute, Bethesda, Maryland; Carroll 
and Taichman, 1992; Carroll et al., 1993) and validated by sequencing. The 
transgene (comprising the IVL promoter and human KLK5FLAG construct) 
was excised from pH3700­pL2 by digestion with SalI, purified and injected 
into the pronuclei of fertilized oocytes from (C57BL/6 x CBA) F1 mice, and 
finally implanted into pseudopregnant females. First generation offspring 
were genotyped by isolating genomic DNA from mouse tail samples using 
the Nucleospin Tissue kit (Macherey­Nagel) and performing PCR using 
allele­specific primers designed to detect the transgene or an internal PCR 
control. The founder mouse was crossed and backcrossed with wild­type 
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IgE antibody (1/2000; Southern Biotech). Signal was developed by addition 
of streptavidin­HRP conjugate (1/2000; Interchim). All samples were ana­
lyzed in duplicate or triplicate by measuring the absorbance at 450 nm using 
a microplate reader (Versamax; Molecular Devices). Concentrations were cal­
culated using standard curves generated with known dilutions of mouse IgG, 
IgG2a, IgG1 (Southern Biotech), and IgE (BD).
Flow cytometry. Single­cell suspensions were prepared from inguinal 
lymph node extracts. Surface antigen staining was performed using the fol­
lowing antibodies (eBioscience): anti­CD45 (clone 30­F11), anti­CD4 (clone 
RM4­5), anti­CD8 (clone 53–6.7), and anti­TCR (clone H57­597). For 
intracellular cytokine staining, isolated cells were activated in complete 
RPMI containing 0.5 µg ml1 phorbol 12 myristate 13­acetate (PMA), 
0.5 µg ml­1 ionomycin and 10 µg ml1 brefeldin A (all from Sigma­Aldrich) 
for 4 h. After surface staining, cells were fixed and permeabilized using Cyto­
fix/Cytoperm solution (BD). Cells were washed in perm/wash buffer and 
incubated for 30 min at 4°C with different antibody combinations specific 
for murine cytokines (all from eBioscience) diluted in perm/wash buffer: 
anti­Il4 (clone 11B11), anti–IL­13 (clone eBio13A), anti­Il17 (clone eBio17B7), 
and TNF (clone MP6­XT22). Immunostained cells were analyzed by flow 
cytometry using a FACS Aria flow cytometer (BD).
Statistical analysis. Experiments were repeated at least three times and 
p­values were calculated using the Mann­Whitney t test. P < 0.05 was con­
sidered significant.
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